Aktive Positionen von Joseph Higgins
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | 01.01.2020 | - |
| Gründer | 01.01.2020 | - | |
| Präsident | 01.01.2020 | - |
Karriereverlauf von Joseph Higgins
Statistik
International
| Vereinigte Staaten | 2 |
Operativ
| Director/Board Member | 1 |
| Founder | 1 |
| President | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Health Technology |
- Börse
- Insiders
- Joseph Higgins
- Erfahrung
